Menopause, a normal process of aging, is defined as the absence of menstrual flow for 12 consecutive months. Menopause typically affects women between the ages of 40 to 58 years, with a median onset at 47.5 years and ending at a median age of 51.4 years.[@CIT0001],[@CIT0002] It is estimated that 50--75% of peri-menopausal and post-menopausal women experience menopause symptoms during peri-menopause, menopause and into post-menopause,[@CIT0003]--[@CIT0005] which can include hot flashes and night sweats (vasomotor symptoms), low self-rated health, sexual difficulties, insomnia,[@CIT0006],[@CIT0007] anxiety and depression.[@CIT0004],[@CIT0008] These symptoms can be severe and last for 10 years or more after the menopause transition.[@CIT0006] A systemic review indicated that whereas vasomotor systems are highly prevalent in most societies,[@CIT0009] geographical location and ethnicity influence the prevalence of certain symptoms.[@CIT0010] For example, age at menopause was lower in women from African, Latin American, Asian and Middle Eastern countries as compared with Europe, Australia and the USA. Vasomotor symptoms were reported to be lower in Middle Eastern countries than Western countries, and European women or women with Latin American ethnicity had predominantly central nervous system symptoms such as mood changes, sleeplessness and irritability.

Age of onset of menopause is also influenced by other factors: lower socioeconomic status (SES), lower level of education and smoking were associated with earlier onset of menopause, whereas while being overweight or partaking in physical exercise was modestly associated with later onset of menopause, there was no clear association.[@CIT0011]

In addition to affecting quality of life,[@CIT0012],[@CIT0013] menopause symptoms have a considerable economic burden, with incremental total health expenditures of nearly 500 US\$ per case.[@CIT0014] In one study,[@CIT0015] severe vasomotor symptoms were associated with 82% higher all-cause outpatient visits and 121% higher specialized outpatient visits. Other studies have reported the extent that menopausal symptoms have interfered with productivity at work.[@CIT0013],[@CIT0016]

Limited real-world data are available regarding menopause symptoms in Israel. This study describes the prevalence of menopause symptoms in Israel, characterizes women with regard to socioeconomic variables and comorbidities, and compares the use of healthcare services among women with diagnosed menopause symptoms to that of a matched control group.

Methods {#S0002}
=======

Data Source {#S0002-S2001}
-----------

This retrospective cohort study was conducted using the computerized databases of Maccabi Healthcare Services (MHS), a nationwide healthcare insurer-provider representing a quarter of the population in Israel, with 2.3 million members. The MHS database contains longitudinal anonymized data that are automatically collected since 1993 for a stable population (with less than 1% of members moving out each year), including laboratory results from a single central laboratory and pharmacy prescription and purchase data. MHS uses the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) coding systems, as well as self-developed coding systems to provide more granular diagnostic information. Procedures are coded using Current Procedural Terminology (CPT) codes. This study was reviewed and approved by the Institutional Review Board of the Assuta Medical Center in Israel (0101--17-BBL).

Study Population {#S0002-S2002}
----------------

In this retrospective cohort study, we identified female MHS members aged 45 to 54 with at least 2 diagnoses for general menopausal and post-menopausal disorders (primary, secondary, or tertiary ICD-9-CM codes of 627.xx) in their electronic medical record between the years 2010 to 2015 with no evidence of a cancer diagnosis before index date (due to hot flashes being a side effect of some anti-cancer treatments).[@CIT0002] A total of 18,483 women aged 45 to 54 years were identified and of these, 1432 were excluded due to a prior cancer diagnosis (based on the MHS cancer registry which uses diagnosis data from the Israel Ministry of Health, linked to cancer medication approvals and pathology reports from MHS).

Women with a menopausal disorder (symptomatic women) were matched individually (one-to-one) to women without any menopausal disorder (reference group), on birth year and geographical area (particular MHS health center).

Index date for symptomatic women was defined as the date of the first menopause diagnosis and women in the reference group were assigned the same index date as their corresponding matched pair.

Women with less than one year of healthcare registration in MHS before or after index date were excluded.

Study Variables {#S0002-S2003}
---------------

Demographic and clinical data collected included age at index, SES, district, smoking, and prevalence of comorbid conditions. SES was categorized into quartiles based on the poverty index of the member's enumeration area, as defined by the 2008 National Census.[@CIT0017] The poverty index is based on several parameters including household income, education level, crowding, physical living conditions and car ownership. Smoking status was identified from physician notes in the database.

Comorbidities at baseline were identified using validated MHS registries (diabetes mellitus, hypertension, chronic obstructive pulmonary disease (COPD), cardiovascular disease, chronic kidney disease and osteoporosis) before index date.[@CIT0018]--[@CIT0020] In addition, comorbidity was measured by the Deyo-Charlson Comorbidity Index[@CIT0021] and augmented using the MHS chronic disease registries. All comorbidities were measured in the 1-year pre-index period.

Other comorbidities and outcomes included prevalence of selected comorbidities, procedures, and medications purchased, in the 1 year baseline period and 1-year post-index period. Comorbidities studied were identified using primary MHS registries or ICD-9-CM codes: major depression (296.2x-296.3x, or 311.xx), other depression (298.0x, 300.4x, or 309.0x-309.1x), anxiety (293.84, 300.0x-300.3x, or 309.21), insomnia (307.41, 307.42, 307.49, 327.0x, or 780.52), osteoporosis (registry), vertebral column fracture (registry), and hip fracture (registry). Medication classes examined were hypnotics, selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and bisphosphonates. Healthcare use included primary care physician (PCP) visits, gynecologist visits, hospitalizations and hysterectomy procedures.

Statistical Analysis {#S0002-S2004}
--------------------

Baseline descriptive characteristics were compared using *t*-tests for continuous variables and chi-square tests for discrete variables. Conditional logistic regression was used to model the likelihood of having any use of services for the 1-year post-index period. The model was adjusted for potential confounders which were found to be significant between the patient groups (p≤0.05), including diabetes mellitus, anxiety, insomnia, osteoporosis or depression before index, use of anti-depression medication, hypnotics or bisphosphonates, SES, smoking and PCP visit in the year before index date. Generalized linear regression modeling (GLM) with negative binomial and log link function was used to model the frequency of hospitalization, physician and gynecology visits in the index year, and the incremental number of visits among symptomatic women versus women in the reference group.

Results {#S0003}
=======

A total of 17,046 women aged 45 to 54 years with two or more menopause diagnoses were identified between the years 2010 to 2015 (cumulative incidence of 8% of the total population during the study period) and successfully matched to women with no menopausal disorders. Mean age was 49.4 years (SD 2.5 years) and the women in the reference group had slightly higher SES (P=0.018). Symptomatic women had a lower prevalence of smoking (12.4% vs 14.0%, P\<0.001), diabetes mellitus (3.7% vs 4.9%, P\<0.001), hypertension (15.4% vs 16.2%, P=0.031) and osteoporosis (2.4% vs 3.4%, P\<0.001 as compared to the women in the reference group at baseline. However, they had a higher proportion of depression (6.1% vs 5.0%), anxiety (6.5% vs 4.7%) and insomnia (2.0% vs 1.3%) (all P\<0.001); and anti-depression (for SSRI 8.3% vs 7.3%, SNRI 2.8% vs 2.3%) and anti-anxiety (11.7% vs 9.2%) medication purchases (all P\<0.001 except SNRI medications P=0.002), as compared to the women in the reference group in the year before index date ([Tables 1](#T0001){ref-type="table"} and [[S1](https://www.dovepress.com/get_supplementary_file.php?f=246113.docx)]{.ul}). Bisphosphonate use was lower among symptomatic women (0.7% vs 1.0%, P\<0.001).Table 1Demographic and Clinical Characteristics of the Study Population for Matched Cohort of Symptomatic Women vs Women in the Reference Group at Index Date (Date of First Menopause Symptom). (N=34,092). All N (%) Unless Otherwise StatedReference Group (Controls) n=17,046Symptomatic Women (Cases) n=17,046P-value**Demographic**Age y, median (IQR)49.00 (47.00, 51.00)49.00 (48.00, 51.00)0.802District Centre10,808 (63.4%)10,808 (63.4%)1.00 North3,088 (18.1%)3,088 (18.1%) South3,150 (18.5%)3,150 (18.5%)Socioeconomic status\* 1st (lowest)5,521 (32.4%)5,249 (30.8%)0.018 2nd3,422 (20.1%)3,512 (20.6%) 3rd3,381 (19.8%)3,455 (20.3%) 4th (highest)4,722 (27.7%)4,830 (28.3%)**Clinical indices**Smoking status Never14,119 (82.8%)14,552 (85.4%)\<0.001 Ever2,384 (14.0%)2,118 (12.4%) Unknown543 (3.2%)376 (2.2%)Deyo-Charlson Index 02,725 (16.0%)2,796 (16.4%)0.344 1886 (5.2%)887 (5.2%) 3285 (1.7%)261 (1.5%) ≥4127 (0.7%)103 (0.6%)Comorbidities Diabetes mellitus831 (4.9%)631 (3.7%)\<0.001 Cardiovascular disease613 (3.6%)607 (3.6%)0.861 Hypertension2,765 (16.2%)2,620 (15.4%)0.031 Chronic kidney disease475 (2.8%)459 (2.7%)0.596 COPD99 (0.6%)68 (0.4%)0.016 Osteoporosis580 (3.4%)416 (2.4%)\<0.001 Major depression82 (0.5%)103 (0.6%)0.122 Other depression848 (5.0%)1,037 (6.1%)\<0.001 Anxiety808 (4.7%)1,107 (6.5%)\<0.001 Insomnia228 (1.3%)347 (2.0%)\<0.001Hysterectomy 1 year before index81 (0.5%)100 (0.6%)0.157**Medication use within 6 months before index**Anti-anxiety (hypnotics)1,575 (9.2%)2,001 (11.7%)\<0.001SSRI1,236 (7.3%)1,416 (8.3%)\<0.001SNRI388 (2.3%)476 (2.8%)0.002Bisphosphonates177 (1.0%)114 (0.7%)\<0.001[^1][^2]

In the baseline year, symptomatic women had a higher frequency of hospitalizations (5.9% vs 5.3%, P=0.02), PCP and gynecologist visits (at least one visit: 93.0% vs 87.9% and 57.8% vs 44.5%, respectively, both P\<0.001); however no difference was seen in median length of stay among those hospitalized or median number of gynecology visits ([Table 2](#T0002){ref-type="table"}). In addition a small percent of women had hysterectomy procedures prior to index date, with no difference between symptomatic and women in the reference group (0.6% vs 0.5%, P=0.16).Table 2Healthcare Utilization in the 1- Year Baseline Period (N=34,092)Reference Group (Controls) n=17,046Symptomatic Women (Cases) n=17,046P-value**Hospitalization** N (%)902 (5.3%)1,002 (5.9%)0.018 Median (IQR) number of nights in the baseline year for those hospitalized2 (1,4)2 (1,4)0.215 Median (IQR) number of separate hospitalizations1 (1,1)1 (1,1)0.840  186.3%85.9%0.663  210.0%10.0%  ≥33.8%4.1%**PCP visits** ≥114,987 (87.9%)15,856 (93.0%)\<0.001 ≥59,403 (55.2%)10,633 (62.4%)\<0.001 Median (IQR)6 (3,10)7 (4, 11)\<0.001**Gynecologist visits** ≥17,590 (44.5%)9,849 (57.8%)\<0.001 Median (IQR)2 (1, 3)2 (1,3)0.084[^3]

One-year post-index, symptomatic women were significantly more likely than women in the reference group to have a diagnosis of depression (not major depression), anxiety and osteoporosis for ages 44--52, and insomnia, across all age groups ([Figure 1](#F0001){ref-type="fig"}).Figure 1One-year post-index prevalence of comorbid conditions for symptomatic women (cases) versus women in the reference group (controls), by age, N=34,092. \*Significant difference between menopause and control cohorts.

Correspondingly, SSRI, SNRI and hypnotic use were significantly higher for symptomatic women for ages 44--52 ([Figure 2](#F0002){ref-type="fig"}).Figure 2One-year post-index prevalence of medication for symptomatic women (cases) versus women in the reference group (controls), by age N=34,092. \*Significant difference between menopause and control cohorts.**Abbreviations:** SSRI, selective serotonin reuptake inhibitors; SNRI, serotonin-norepinephrine reuptake inhibitor.

Categorical healthcare utilization (yes/no) for the one-year post-index prevalence showed a slight difference in hospitalization, and significantly higher PCP and gynecology visits for all age groups ([Figure 3](#F0003){ref-type="fig"}), and hysterectomy procedures ([[Figure S1](https://www.dovepress.com/get_supplementary_file.php?f=246113.docx)]{.ul}) for symptomatic women as compared to women in the reference group, with the following adjusted odds ratios (95% CI): hospitalizations 1.10 (1.01--1.21), PCP visits 1.90 (1.73--2.08), gynecologist visits 24.84 (22.36--27.59) and hysterectomy procedures 2.26 (1.63--3.14) ([Table 3](#T0003){ref-type="table"}).Table 3Adjusted Odds Ratios Associated with Categorical Healthcare Utilization and Hysterectomy Procedures (Yes/No) in the Index Year (Using Conditional Logistic Regression)Reference Group (Controls) n=17,046\
N (%)Symptomatic Women (Cases) n=17,046\
N (%)Adjusted OR^a^ (95% CI)Hospitalizations960 (5.6%)1,070 (6.3%)1.102 (1.006, 1.207)PCP visits15,075 (88.4%)16,086 (94.4%)1.901 (1.734, 2.084)Gynecologist visits7,401 (43.4%)16,196 (95.0%)24.835 (22.357, 27.589)Hysterectomy procedures (n=31,688)52 (0.3%)121 (0.8%)2.262 (1.630, 3.140)[^4][^5] Figure 3One-year post-index prevalence of healthcare utilization for symptomatic women (cases) versus women in the reference group (controls), N=34,092. \*Significant difference between menopause and control cohorts.

Adjusted odds ratios associated with frequency of hospitalizations, PCP visits and gynecologist visits for symptomatic women were statistically significant: hospitalizations 1.12 (1.03--1.22), PCP visits 1.15 (1.13--1.18) and gynecologist visits 2.15 (2.09--2.22), and symptomatic women had an increase in added visits per year of 1.07 (0.89, 1.25) to a PCP and 1.09 (1.03, 1.14) to a gynecologist ([Table 4](#T0004){ref-type="table"}).Table 4Adjusted Odds Ratios Associated with the Frequency of Hospitalizations, Primary Care Physician Visits and Gynecologist Visits Using for Index Year (Using Generalized Linear Regression Modeling)Reference Group (Controls)\
n=17,046,\
Mean (SD)Symptomatic Women (Cases) n=17,046,\
Mean (SD)Adjusted OR^a^ (95% CI)Added Number of Visits per Patient for Index YearHospitalizations0.069 (0.326)0.078 (0.348)1.122 (1.033, 1.218)0.01 (0,0.020)PCP visits6.912 (6.506)8.23 (6.926)1.154 (1.128, 1.181)1.07 (0.890,1.25)Gynecologist visits0.941 (1.65)2.052 (2.14)2.154 (2.093, 2.216)1.09 (1.030,1.14)[^6][^7]

More detailed comparison of study groups is given in [[Tables S2](https://www.dovepress.com/get_supplementary_file.php?f=246113.docx)]{.ul} and [[S3](https://www.dovepress.com/get_supplementary_file.php?f=246113.docx)]{.ul}.

Discussion {#S0004}
==========

The results of this analysis indicate that symptomatic women are associated with an increased burden of disease and healthcare utilization including hospitalizations, PCP visits, gynecologist visits and a greater likelihood of undergoing hysterectomy in the year following diagnosis. The incremental increase in health costs for physician visits and hospitalizations was 574 shekels per woman per year equal to 149 purchasing power parity dollars (Ministry of Health prices, 2015). This annual direct per-person costs of menopausal symptoms are comparable to the one calculated in the US (\$248) that was based on expert clinical opinion regarding 28 medical conditions common to menopausal women.[@CIT0022]

Symptomatic women had a lower proportion of smokers, diabetes mellitus, hypertension and osteoporosis. This appears to be inconsistent with some published studies that indicate that smoking may be associated with early onset of menopause.[@CIT0023]--[@CIT0027] However, 2.2% of the symptomatic women and 3.2% of women in the reference group had unknown smoking status in their medical notes, which could affect the overall smoking status of the two groups.

In addition we would expect to see a higher proportion of women with osteoporosis among symptomatic women as onset of menopause is associated with the development of osteoporosis due to the decrease in estrogen over this time period. We did not observe this difference at baseline, however we do observe an increase in osteoporosis diagnosis after index date among symptomatic women which may be as a result of increased PCP and gynecology consultations and hence increased osteoporosis testing as a result of those visits.[@CIT0028]

Symptomatic women had a higher proportion of depression, anxiety and insomnia in the year before and after index date as compared to women in the reference group. Study findings suggest that documented history of depression, anxiety and insomnia and related medication purchases are important predispositions for menopause symptoms or may indicate a lag between symptom initiation and treatment of menopausal symptoms.[@CIT0027] These symptoms are typically reported during the late premenopausal years when a decline in estrogen production is expected and before a menopausal diagnosis is given. These symptoms were also more likely to be reported among symptomatic women in the year following index date as typical characteristics of menopause.[@CIT0003] Our results show a lower proportion of women who were diagnosed with these conditions among symptomatic women as compared to other studies.[@CIT0002],[@CIT0029] Under-reporting of these symptoms may be due to cultural factors which influence symptom perception[@CIT0030],[@CIT0031] or due to the perceived "stigma" of suffering from mental illness.[@CIT0032] As awareness increases and more women request medical help, the burden on the health system is expected to rise.

Up to 95% of symptomatic women visited their PCP and gynecologist during the year following index date which is consistent with a study from Australia where 86% of women reported having consulted physicians for their menopausal symptoms[@CIT0033] and as reported in the STRIDE study which found greater healthcare resource use for women experiencing hot flashes.[@CIT0034] Our study results are also in line with a previous report demonstrating an increase of 2.8 visits to care providers over a 6-month period.[@CIT0035] The high proportion of women visiting physicians in our cohort (reaching 8.4 visits annually among symptomatic women) could be due to the high accessibility of cost-free ambulatory medical services in Israel.[@CIT0036],[@CIT0037] However, the number of gynecologists with a sub-specialty in menopause is low and therefore women may not be getting the response they require, and move from physician to physician. The increase in hysterectomy procedures among cases could be connected to increased physician visits, as there is increased likelihood of other findings such as uterine myoma, uterine polyps or prolapse sometimes resulting in hysterectomy. In addition, older age is a risk factor for uterine atypical hyperplasia of carcinoma, also treated by hysterectomy.

Other studies also report an increase in healthcare utilization including hospitalization and emergency room services[@CIT0016],[@CIT0038] and the direct costs of care are similar or greater than a number of other medical conditions such as esophageal disorders and osteoporosis.[@CIT0022]

Awareness of menopause and attitudes towards it can influence the degree of symptoms. Women who had a negative attitude suffered more from depression or sleeping disorders than those with a positive one.[@CIT0039] In addition, lack of knowledge of the natural process of menopause and lifestyle interventions are a major challenge to symptom control.[@CIT0040] Management strategies should include empowering women to participate in their care that will improve their sense of control and overall care,[@CIT0041],[@CIT0042] together with exercise and diet recommendations, including isoflavones, calcium and vitamin D which may have favorable effects on menopausal symptoms and quality of life[@CIT0043] and sexual health.[@CIT0044]

The gold standard treatment for women that seek control of their symptoms is hormone replacement therapy (HRT), but the optimal course of treatment is unclear due to mixed results from studies.[@CIT0045],[@CIT0046] Initial interpretation of the Women's Health Initiative in the early 2000s saw a rapid decrease in HRT use, though current thinking appears to show that women under the age of 60 at the onset of menopause have a favorable risk-benefit profile when taking HRT for short-term relief of vasomotor symptoms.[@CIT0047],[@CIT0048]

Alternative treatments include black cohosh or isoflavones, however the evidence for their benefit and safety from randomized-controlled trials is poor.[@CIT0049],[@CIT0050]

This study is a large population based sample, with longitudinal data allowing collection of real-world data and analysis of a wide range of symptoms. However, it may have limitations associated with its retrospective cohort design. Data on purchases made outside of MHS pharmacies were not captured; however, patients are unlikely to buy medications outside of MHS due to their discounted price within MHS. It should also be noted that actual medication use is unknown, as dispensed medications may not be consumed. However, previous studies have demonstrated the validity of this approach for measuring compliance with chronic medications.[@CIT0051]

Conclusion {#S0005}
==========

Menopausal symptoms are associated with increased burden of disease and healthcare utilization, including hospitalizations, physician visits, gynecologist visits and greater likelihood of undergoing hysterectomy. This burden is expected to rise further as awareness and social acceptance of peri- and post-menopausal symptoms increase. Better education on menopause for physicians and effective communication between healthcare providers and patients can help to better manage menopausal symptoms. There is an urgent need for doctors who specialize in menopause in order to help reduce the burden of unnecessary physician visits.

This study was presented as a poster at the ISPOR (International Society for Pharmacoeconomics and Outcomes Research) European conference, November 2019, Copenhagen Denmark.

Synopsis {#S0006}
========

Medically documented menopausal symptoms are associated with increased burden of disease and healthcare utilization and greater likelihood of undergoing hysterectomy within one year of diagnosis.
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[^1]: **Notes:** \*Socioeconomic status is based on the poverty index of the member's enumeration area, as defined by the 2008 National Census. The poverty index is based on parameters including household income, educational level, crowding, physical conditions and car ownership. A higher score indicates higher level of SES.

[^2]: **Abbreviations:** COPD, chronic obstructive pulmonary disease; SSRI, selective serotonin reuptake inhibitors; SNRI, serotonin-norepinephrine reuptake inhibitor.

[^3]: **Abbreviation:** PCP, primary care physician.

[^4]: **Notes:** ^a^Adjusted for age at diagnosis, SES, smoking, PCP visits, comorbidities at index: diabetes mellitus, osteoporosis, depression, anxiety, insomnia, drug use within 6 months before index: hypnotics, SSRI, SNRI, bisphosphonates.

[^5]: **Abbreviations:** PCP, primary care physician; SES, socioeconomic status; SSRI, selective serotonin reuptake inhibitors; SNRI, serotonin-norepinephrine reuptake inhibitor.

[^6]: **Notes:** ^a^Adjusted for age at diagnosis, SES, smoking, PCP visits, comorbidities at index: diabetes, Osteoporosis, depression, anxiety, insomnia, drug use within 6 months before index: hypnotics, SSRI, SNRI, bisphosphonates.

[^7]: **Abbreviations:** PCP, primary care physician; SES, socioeconomic status; SSRI, selective serotonin reuptake inhibitors; SNRI, serotonin-norepinephrine reuptake inhibitor.
